Nuvation Bio outlines first-line IBTROZI growth strategy with 50-month median DOR amid expanding global partnerships
Source: SeekingAlpha
2026-03-03 02:38:32 ET
More on Nuvation Bio
- Nuvation Bio Inc. (NUVB) Q4 2025 Earnings Call Transcript
- Nuvation Bio Inc. 2025 Q4 - Results - Earnings Call Presentation
- Nuvation Bio: Why Ibtrozi's 6x Adoption Rate Changes The Thesis (Rating Upgrade)
- Seeking Alpha’s Quant Rating on Nuvation Bio
- Historical earnings data for Nuvation Bio
Read the full article on Seeking Alpha
For further details see:
Nuvation Bio outlines first-line IBTROZI growth strategy with 50-month median DOR amid expanding global partnerships
Nuvation Bio Inc. Class A
NASDAQ: NUVB
NUVB Trading
-2.01% G/L:
$4.625 Last:
1,569,647 Volume:
$4.65 Open:
NUVB Latest News
March 03, 2026 03:57:55 pm
Nuvation Bio Stock Up 130% This Past Year as One Fund Discloses $3 Million Buy
March 02, 2026 04:05:00 pm
Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
NUVB Stock Data
$1,967,863,905
245,468,738
0.19%
71
N/A
Biotechnology & Life Sciences
Healthcare
US
New York
